Alector, Inc. (NASDAQ:ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company is advancing its Alector Brain Carrier (ABC) platform, which includes treatments for Alzheimer's and Parkinson's diseases. Alector operates within the Zacks Medical - Biomedical and Genetics industry, competing with other biotech firms in the race to develop innovative treatments.
On February 26, 2026, Wong-Sarad Grace, the Principal Accounting Officer of Alector, sold 4,079 shares of the company's common stock at $2.50 per share. Despite this sale, Grace still holds 118,903 shares. This transaction is part of the company's ongoing financial activities, as highlighted by the official SEC filing.
Alector recently reported a quarterly loss of $0.34 per share, which was better than the expected $0.39 loss, resulting in a 13.71% earnings surprise. This performance is notable given the company's consistent track record of surpassing consensus EPS estimates over the last four quarters. However, the company is not yet profitable, as indicated by its negative P/E ratio of -1.84.
The company's revenue for the quarter ending December 2025 was $6.24 million, exceeding expectations by 103.43%. Despite this, it represents a significant drop from the $54.24 million reported a year ago. Alector has outperformed consensus revenue estimates in three of the last four quarters, demonstrating its ability to exceed market expectations.
Alector's financial position includes $256 million in cash, cash equivalents, and investments, which is expected to support operations through 2027. The company's current ratio of 3.83 indicates a strong ability to cover short-term liabilities. However, its enterprise value to operating cash flow ratio of -1.36 suggests challenges in generating positive cash flow from operations.
